Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Maze Therapeutics, Inc.NASDAQ: MAZE
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$135K, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 110K USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Accumulated OCI amounts to 0.0% of total assets for MAZE, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $6.02M USD | -18.2% | +29.9% | 0.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $73K USD | -72.3% | +18.5% | 0.0% |
| Mar 2026 | -$26K USD | -620.0% | — | 0.0% | |
| Mar 2026 | -$124K USD | -788.9% | — | 0.0% | |
| Mar 2026 | -$135K USD | — | — | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | -$2.05M USD | -645.3% | — | 0.3% |
| Sep 2026 | -$2.05M USD | -94.1% | — | 0.2% | |
| Dec 2025 | -€204.55M EUR | -18.5% | — | 82.2% | |
| Peer median (excluding MAZE) | — | -94.1% | +24.2% | 0.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.